Skip to main content

Table 2 Bioactivity of Picea mariana bark extracts in PC12-AC grown in hyperglycemic media

From: Growth environment and organ specific variation in in-vitro cytoprotective activities of Picea mariana in PC12 cells exposed to glucose toxicity: a plant used for treatment of diabetes symptoms by the Cree of Eeyou Istchee (Quebec, Canada)

Extract IDa

Bioactivity in hyperglycemic mediab

1FB

Mitogenic

1BB

Mitogenic

2FB

Cytoprotective

2BB

Cytoprotective

3FB

Cytoprotective

3BB

Cytoprotective

4FB

Cytoprotective

4BB

Cytoprotective

5FB

None

5BB

None

6FB

Cytoprotective/Mitogenic

6BB

Cytoprotective/Mitogenic

7FB

Cytoprotective

7BB

Cytoprotective

11FB

None

11BB

Cytoprotective

14FB

None

14BB

None

  1. aThe extract ID code defines the growth environment (Area#1–21, Fig. 1), habitat (B Bog or F forest) and organ (B bark). For example, 1FB is an extract prepared from bark collected in a forest habitat at location #1
  2. bBioactivity was classified using a 96 h treatment in hyperglycemic (150 mM) serum-free media. Viable PC12-AC cell number following extract treatment was established using the WST-1 assay compared to standard curves of known cell number. Vehicle control was 0.1% DMSO. Extracts that at two or more concentrations increased viable cell number to values significantly higher than the normoglucose controls (> 100%) were classified as mitogenic, those which significantly protected cells from high glucose toxicity without apparent mitogenic activity were classified as cytoprotective, and those which enhanced glucotoxicity were classified as cytotoxic. Samples classified with dual bioactivities (ie. Cytoprotective/Mitogenic) are possible when two concentrations satisfy our definition of one bioactivity (ie. Cytoprotective) and two other concentrations from the same sample are in another category (ie. Mitogenic). Statistics were ANOVA, post-hoc Tukey tested vs. vehicle-treated cultures in normo- or high glucose media. All concentration-response data and statistical analyses are presented in Additional file 2: Figure S2